Paying users zone. Data is covered by 
.
Get 1 month access to Celgene Corp. for $17.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Celgene Corp. (CELG)
Financial Reporting Quality: Aggregate Accruals
Difficulty: Advanced
Earnings can be decomposed into cash and accrual components. The accrual component (aggregate accruals) has been found to have less persistence than the cash component, and therefore (1) earnings with higher accrual component are less persistent than earnings with smaller accrual component, all else equal; and (2) the cash component of earnings should receive a higher weighting evaluating company performance.
Balance-Sheet-Based Accruals Ratio
Celgene Corp., balance sheet computation of aggregate accruals
USD $ in millions
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Operating Assets | ||||||
| Total assets | |
|
|
|
|
|
| Less: Cash and cash equivalents | |
|
|
|
|
|
| Less: Debt securities available-for-sale | |
|
|
|
|
|
| Less: Equity investments with readily determinable fair values | |
|
|
|
|
|
| Less: Marketable securities available-for-sale | |
|
|
|
|
|
| Operating assets | |
|
|
|
|
|
| Operating Liabilities | ||||||
| Total liabilities | |
|
|
|
|
|
| Less: Short-term borrowings and current portion of long-term debt | |
|
|
|
|
|
| Less: Long-term debt, net of discount, excluding current portion | |
|
|
|
|
|
| Operating liabilities | |
|
|
|
|
|
| Net operating assets1 | |
|
|
|
|
|
| Balance-sheet-based aggregate accruals2 | |
|
|
|
|
|
| Ratio | ||||||
| Balance-sheet-based accruals ratio3 | |
|
|
|
|
|
| Benchmarks | ||||||
| Balance-Sheet-Based Accruals Ratio, Competitors4 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Balance-Sheet-Based Accruals Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Balance-Sheet-Based Accruals Ratio, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20).
1 2018 Calculation
Net operating assets = Operating assets – Operating liabilities
= – =
2 2018 Calculation
Balance-sheet-based aggregate accruals = Net operating assets 2018 – Net operating assets 2017
= – =
3 2018 Calculation
Balance-sheet-based accruals ratio = 100 × Balance-sheet-based aggregate accruals ÷ Avg. net operating assets
= 100 × ÷ [( + ) ÷ 2] =
4 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Balance-sheet-based accruals ratio | Ratio is found by dividing balance-sheet-based aggregate accruals by average net operating assets. | Using the balance-sheet-based accruals ratio, Celgene Corp. deteriorated earnings quality from 2017 to 2018. |
Cash-Flow-Statement-Based Accruals Ratio
Celgene Corp., cash flow statement computation of aggregate accruals
USD $ in millions
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Net income | |
|
|
|
|
|
| Less: Net cash provided by operating activities | |
|
|
|
|
|
| Less: Net cash used in investing activities | |
|
|
|
|
|
| Cash-flow-statement-based aggregate accruals | |
|
|
|
|
|
| Ratio | ||||||
| Cash-flow-statement-based accruals ratio1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Cash-Flow-Statement-Based Accruals Ratio, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Cash-Flow-Statement-Based Accruals Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Cash-Flow-Statement-Based Accruals Ratio, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20).
1 2018 Calculation
Cash-flow-statement-based accruals ratio = 100 × Cash-flow-statement-based aggregate accruals ÷ Avg. net operating assets
= 100 × ÷ [( + ) ÷ 2] =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Cash-flow-statement-based accruals ratio | Ratio is found by dividing cash-flow-statement-based aggregate accruals by average net operating assets. | Using the cash-flow-statement-based accruals ratio, Celgene Corp. deteriorated earnings quality from 2017 to 2018. |